Health News Roundup: Drug Recall, Political Investigations, and Celebrity Cancer
The FDA announced a nationwide recall of three lots of epinephrine injection due to sterility issues and particulate matter. In other news, an armed man was arrested at a campaign event for Ohio gubernatorial candidate Amy Acton, and the FBI's investigation into Anthony Fauci over COVID-19 origins remains unclear. Additionally, a phase III trial for pelacarsen failed to meet primary endpoints, and the DOJ reached an agreement with Mount Sinai regarding gender-affirming care for minors.
The recalled epinephrine lots, made by American Regent, carry sterility concerns and particles that could block blood vessels. Separately, the FDA issued interim compounding guidelines for initial intravenous nutrition for newborns to ease supply shortages. The Justice Department also finalized an agreement with Mount Sinai, requiring the system to stop providing gender-affirming care to minors and pay penalties.
Novartis reported that its late-stage pelacarsen trial failed its main objectives. The HHS Office of Minority Health cut over half its grants, focusing on infertility causes and exercise promotion. Colorado regulators learned of liver damage from a marijuana sleep aid prior to public warnings, and many patients may not actually have penicillin allergies.
These developments could erode public trust in drug safety and regulatory oversight, especially given the recall and delayed liver injury warnings. The DOJ's Mount Sinai agreement may influence hospital policies nationwide, while the failed pelacarsen trial could delay cardiovascular treatment options. Measles outbreaks and HIV funding cuts may leave vulnerable populations at higher risk, and ongoing political probes could shape how patients perceive medical guidance and access care.